Riskpilot← Back to searchSign inGet full accessCryoIQ AB
ABActiveOrg 5590551676Apelrödsvägen 1Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20160 employees
Revenue 2025
SEK 0
EBITDA margin
—
-11% vs 2024
Equity ratio
27.3%
Financial strength
Net profit 2025
SEK -10K
-11% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -10K | -11% |
| Net profit | SEK -10K | -11% |
| Total assets | SEK 22K | -33% |
| Equity | SEK 6K | -65% |
| Employees | 0 | — |
Legal name
CryoIQ AB
Org number
5590551676
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
15 mars 2016
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolagets ska bedriva försäljning och tillverkning av medicin- teknisk utrustning samt därmed förenlig verksamhet.
Address
Apelrödsvägen 1
Email
info@skafte.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −16 | −8 | −3 | −9 | −10 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −16 | −8 | −3 | −9 | −10 |
| Net financials | — | — | — | — | — |
| Profit before tax | −16 | −8 | −3 | −9 | −10 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −16 | −8 | −3 | −9 | −10 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 46 | 38 | 29 | 33 | 22 |
| Equity | 36 | 28 | 25 | 17 | 6 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 10 | 10 | 4 | 16 | 16 |
| Total debt | 10 | 10 | 4 | 16 | 16 |
EBITDA margin
-1000000.0%
This company
15.8%
Market median
-6329214% vs market
20212025
Equity ratio
27.3%
This company
38.2%
Market median
-29% vs market
20212025
Return on equity
-166.7%
This company
18.4%
Market median
-1006% vs market
20212025
Net profit margin
-1000000.0%
This company
8.1%
Market median
-12345779% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
2.67×
This company
0.62×
Market median
-331% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
US Chief Executive Officer | Chief Executive Officer | 2025 |
RM | Audit | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2021 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Skalab Affärsutveckling AB
CryoIQ AB Board members of CryoIQ AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ulf Stefan Skafte | Chief Executive Officer | 0 companies |
| Rolf Martin von Brömsen | Audit | 0 companies |
| Robin Ulf Skafte | Deputy Board Member | 0 companies |
| Philippe André Bertil Émile Rembry | Deputy Board Member | 0 companies |